Dr Reddy's completed a ₹445 crore deal to acquire Johnson & Johnson's Stugeron brand, adding a strong anti-vertigo drug and expanding its CNS portfolio across 18 markets. SEBI analysts said cost and integration risks weighed on near-term sentiment, but the deal is strategically positive. Key levels: support ₹1240-1260, resistance ₹1320-1340; breakout could target ₹1400-1450.